

Transaction Contacts

Coverage Team: ECM Team:
Dan Dubin, M.D. Patrick Morley,
Gabriel Cavazos
Brian Swanson



\$250 Million
Follow-On Offering

svb Securities
Joint Bookrunner
June 2023

SVB Securities Serves as Joint Bookrunner for Zentalis Pharmaceuticals' (Nasdaq: ZNTL) \$250 Million Follow-On Offering

Key Transaction Highlights

- Underwritten confidentially marketed deal that launched on June 13th and priced on June 15th pre-market open.
- Deal consisted of 11,032,656 shares of common stock at a price of \$22.66 per share, representing an 8.0% discount to last sale.
- Well oversubscribed from both new and existing investors
- Zentalis intends to use the net proceeds of the offering to fund ongoing and planned clinical trials, working capital, and other general corporate purposes.
- This is SVB Securities' 5th bookrun offering for Zentalis and 31st bookrun equity offering in 2023.

If you would like to unsubscribe from this distribution, click [here](#). If you would like to unsubscribe from all SVB Securities distributions, click [here](#).

THIS EMAIL IS FOR INFORMATIONAL PURPOSES ONLY AND IS BEING FURNISHED TO INVESTMENT BANKING CLIENTS OF SVB SECURITIES LLC. THE INFORMATION INCLUDED HEREIN IS FOR YOUR INFORMATION ONLY AND MAY NOT BE REPRODUCED FOR OR REDISTRIBUTED TO ANY OTHER PURPOSES. THESE SECURITIES HAVE BEEN SOLD. THIS EMAIL IS NOT AN OFFER TO SELL, AND IS NOT SOLICITING AN OFFER TO BUY, ANY SECURITIES.

BOSTON
53 State Street
40th Floor
Boston, MA 02109

CHARLOTTE
2151 Hawkins Street
Suite 1025
Charlotte, NC 28203

NASHVILLE
40 Burton Hills Boulevard
Suite 200
Nashville, TN 37215

NEW YORK
1301 Avenue of the
Americas
12th Floor
New York, NY 10019

SAN FRANCISCO
255 California Street
12th Floor
San Francisco, CA 94111

An SVB Company
svbsecurities.com